Malta - English - Medicines Authority

macarthys laboratories limited bampton road, harold hill, romford essex, rm3 8ug, united kingdom - methadone hydrochloride - oral solution - methadone hydrochloride 0.1 % (w/v) - other nervous system drugs

Ireland - English - HPRA (Health Products Regulatory Authority)

ethypharm - methadone hydrochloride - oral solution - 1 milligram(s)/millilitre - drugs used in opioid dependence; methadone

Ireland - English - HPRA (Health Products Regulatory Authority)

taw pharma (ireland) limited - methadone hydrochloride - oral solution - 1 milligram(s)/millilitre - drugs used in opioid dependence; methadone

United States - English - NLM (National Library of Medicine)

lantheus medical imaging, inc. - samarium sm-153 lexidronam pentasodium (unii: 7389yr3oov) (samarium sm-153 - unii:6q1ka41uwm) - samarium sm-153 50 mci in 1 ml - quadramet® is indicated for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan. quadramet® is contraindicated in patients who have known hypersensitivity to edtmp or similar phosphonate compounds.

United States - English - NLM (National Library of Medicine)

jazz pharmaceuticals, inc. - samarium sm-153 lexidronam pentasodium (unii: 7389yr3oov) (samarium sm-153 - unii:6q1ka41uwm) - samarium sm-153 50 mci in 1 ml

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - oxycodone hydrochloride; paracetamol - tablets - oxycodone hydrochloride 10 mg; paracetamol 325 mg - paracetamol - paracetamol - for the relief of moderate to moderately severe pain.

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - oxycodone hydrochloride; paracetamol - tablets - paracetamol 325 mg; oxycodone hydrochloride 5 mg - paracetamol, combinations with psycholeptics - paracetamol, combinations with psycholeptics - for the relief of moderate to moderately severe pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - naloxone hydrochloride dihydrate, quantity: 400 microgram/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; dilute hydrochloric acid - this product accepted for registration as 'currently supplied' at the time of commencement of the act. approval for listing of these goods as pharmaceutical benefits were approved as specified in the letter of 29 october 1992 from dr alex proudfoot. indications: for the complete or partial reversal of narcotic depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone and the narcotic-antagonist analgesics such as nalbuphine, methadone and butorphanol. indications as at 8 january 2004: naloxone is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, codeine, morphine and heroin, and the mixed opioid agonist-antagonist analgesics such as pentazocine. naloxone is also indicated for the diagnosis of suspected acute opioid overdosage.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - naloxone hydrochloride dihydrate, quantity: 440 microgram (equivalent: naloxone hydrochloride?, qty 400 microgram) - injection - excipient ingredients: sodium chloride; water for injections; edetate sodium; hydrochloric acid - naloxone is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, codeine, morphine and heroin, and the mixed opioid agonist-antagonist analgesics such as pentazocine. naloxone is also indicated for the diagnosis of suspected acute opioid overdosage.

Israel - English - Ministry of Health

rafa laboratories ltd - fentanyl - patches - fentanyl 12.5 mcg/hour - management of chronic pain and intractable pain requiring opioid analgesia.fenta should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance.